SRBCF News Alert Sirona Biochem Corp. (SRBCF) 0.1084 02/15/2015
Post# of 64074
Posted On: 02/15/2015 3:02:02 PM
Sirona Biochem Corp. (SRBCF) 0.1084 $SRBCF
Sirona Biochem Invited to Present at Dose of the Valley Conference, San Francisco
Marketwired - Mon Jan 26, 8:02AM CST
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) announces that it has been chosen by the Consulate General of Canada to present at the Dose of the Valley conference on February 3-4 in San Francisco, California.
SBM.VN: 0.115 (-0.005)
Sirona Biochem's Subsidiary TFChem Awarded Prestigious French Innovation Trophy
Marketwired - Tue Dec 02, 6:45AM CST
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB), announces that its subsidiary TFChem has been awarded the 6th Haute-Normandie Innovation Trophy from SEINARI -- the Region Haute-Normandie innovation agency. TFChem founder, and Sirona's Chief Scientific Officer, Dr. Géraldine Deliencourt-Godefroy, accepted the award at a ceremony held November 27th in Rouen, France.
SBM.VN: 0.115 (-0.005)
Sirona Biochem Names Attila Hajdu as Chief Business Development Officer
Marketwired - Mon Oct 27, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB), announces that it has named Mr. Attila Hajdu as Chief Business Development Officer. Prior to joining Sirona Biochem, Attila held various senior leadership positions within GlaxoSmithKline (GSK) and Astellas Pharma, accumulating 17 years of experience in Sales, Marketing, R&D Finance, Medical Affairs and Business Development.
SBM.VN: 0.115 (-0.005), GSK: 47.94 (+1.99)
Sirona Biochem Announces Research Collaboration With Aegilops Applications
Marketwired - Mon Oct 20, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) today announced a collaboration with innovative French Company, Aegilops Applications. Aegilops specializes in the protection of plant seeds. The objective of the research collaboration is to develop a novel compound to improve germination and growth in plants, thereby enhancing crop production.
SBM.VN: 0.115 (-0.005)
Sirona Biochem: Obagi Medical Products Begins Manufacturing Scale-Up of Skin Lightening Agent
Marketwire - Tue Oct 07, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) is pleased to announce that its partner Obagi Medical Products Inc., a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc., has started manufacturing scale-up of the innovative skin lightening compound (TFC-849) originally developed by Sirona's scientists in France.
SBM.VN: 0.115 (-0.005), VRX: 167.00 (-0.50), VRX.TO: 207.95 (-1.47)
Sirona Biochem Launches Anti-Aging Preclinical Studies
Marketwire - Mon Sep 22, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) launches the next stage of development for its anti-aging compound library. With recent funding from Bpifrance (the French Public Investment Bank) and the district of Haute Normandie, Sirona Biochem's subsidiary TFChem (France) moves into the next phase of the agreement with the French laboratory Biogalenys.
SBM.VN: 0.115 (-0.005)
Sirona Biochem Announces Positive Results of PK Study for Type 2 Diabetes
Marketwire - Wed Sep 03, 3:30PM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB) today announced that Wanbang Biopharmaceuticals has successfully completed another study in the pre-clinical validation of its anti-diabetic SGLT2 Inhibitor, SBM-TFC-039, for the treatment of Type 2 diabetes.
SBM.VN: 0.115 (-0.005)
Sirona Biochem Launches Global Awareness Campaign With Cousteau Ambassadors' Video
Marketwire - Thu Aug 21, 2:00AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) launches global awareness campaign with ambassadors' video produced by the team of Jean-Michel Cousteau and Fabien Cousteau to represent their support of the glycoprotein project.
SBM.VN: 0.115 (-0.005)
Sirona Subsidiary, TFChem, Receives CDN$1.2 Million for Anti-Aging Project
Marketwire - Tue Aug 12, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the "Company"
announced that its French subsidiary, TFChem, has received confirmation for funding of CDN$1.2 million from Bpifrance (the French Public Investment Bank) and the district of Haute Normandie in the form of a no-interest loan. The funds will be used to advance the organization's anti-aging project.
SBM.VN: 0.115 (-0.005)
Sirona Biochem Announces Successful Synthesis of Anti-Inflammatory Compound for Bloom Burton & Co. Joint Venture
Marketwire - Thu Jul 31, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the "Company" announces the achievement of the first batch of compound in the joint venture with Bloom Burton & Co. ("Bloom Burton" Compounds developed within the framework of the JV will be entering development in the areas of rare inflammatory and infectious diseases.
SBM.VN: 0.115 (-0.005)
Sirona Arranges Convertible Loans
Marketwire - Tue Jul 29, 4:48PM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the "Company" announces that is has entered into convertible loan agreements with arm's length parties (the "Lenders" for the purposes of renewing current outstanding loans in the total amount of $670,000. The original loans were taken out in late 2012 and became due this quarter.
SBM.VN: 0.115 (-0.005)
Sirona Biochem Invited to Present at Dose of the Valley Conference, San Francisco
Marketwired - Mon Jan 26, 8:02AM CST
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) announces that it has been chosen by the Consulate General of Canada to present at the Dose of the Valley conference on February 3-4 in San Francisco, California.
SBM.VN: 0.115 (-0.005)
Sirona Biochem's Subsidiary TFChem Awarded Prestigious French Innovation Trophy
Marketwired - Tue Dec 02, 6:45AM CST
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB), announces that its subsidiary TFChem has been awarded the 6th Haute-Normandie Innovation Trophy from SEINARI -- the Region Haute-Normandie innovation agency. TFChem founder, and Sirona's Chief Scientific Officer, Dr. Géraldine Deliencourt-Godefroy, accepted the award at a ceremony held November 27th in Rouen, France.
SBM.VN: 0.115 (-0.005)
Sirona Biochem Names Attila Hajdu as Chief Business Development Officer
Marketwired - Mon Oct 27, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB), announces that it has named Mr. Attila Hajdu as Chief Business Development Officer. Prior to joining Sirona Biochem, Attila held various senior leadership positions within GlaxoSmithKline (GSK) and Astellas Pharma, accumulating 17 years of experience in Sales, Marketing, R&D Finance, Medical Affairs and Business Development.
SBM.VN: 0.115 (-0.005), GSK: 47.94 (+1.99)
Sirona Biochem Announces Research Collaboration With Aegilops Applications
Marketwired - Mon Oct 20, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) today announced a collaboration with innovative French Company, Aegilops Applications. Aegilops specializes in the protection of plant seeds. The objective of the research collaboration is to develop a novel compound to improve germination and growth in plants, thereby enhancing crop production.
SBM.VN: 0.115 (-0.005)
Sirona Biochem: Obagi Medical Products Begins Manufacturing Scale-Up of Skin Lightening Agent
Marketwire - Tue Oct 07, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) is pleased to announce that its partner Obagi Medical Products Inc., a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc., has started manufacturing scale-up of the innovative skin lightening compound (TFC-849) originally developed by Sirona's scientists in France.
SBM.VN: 0.115 (-0.005), VRX: 167.00 (-0.50), VRX.TO: 207.95 (-1.47)
Sirona Biochem Launches Anti-Aging Preclinical Studies
Marketwire - Mon Sep 22, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) launches the next stage of development for its anti-aging compound library. With recent funding from Bpifrance (the French Public Investment Bank) and the district of Haute Normandie, Sirona Biochem's subsidiary TFChem (France) moves into the next phase of the agreement with the French laboratory Biogalenys.
SBM.VN: 0.115 (-0.005)
Sirona Biochem Announces Positive Results of PK Study for Type 2 Diabetes
Marketwire - Wed Sep 03, 3:30PM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB) today announced that Wanbang Biopharmaceuticals has successfully completed another study in the pre-clinical validation of its anti-diabetic SGLT2 Inhibitor, SBM-TFC-039, for the treatment of Type 2 diabetes.
SBM.VN: 0.115 (-0.005)
Sirona Biochem Launches Global Awareness Campaign With Cousteau Ambassadors' Video
Marketwire - Thu Aug 21, 2:00AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) launches global awareness campaign with ambassadors' video produced by the team of Jean-Michel Cousteau and Fabien Cousteau to represent their support of the glycoprotein project.
SBM.VN: 0.115 (-0.005)
Sirona Subsidiary, TFChem, Receives CDN$1.2 Million for Anti-Aging Project
Marketwire - Tue Aug 12, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the "Company"
announced that its French subsidiary, TFChem, has received confirmation for funding of CDN$1.2 million from Bpifrance (the French Public Investment Bank) and the district of Haute Normandie in the form of a no-interest loan. The funds will be used to advance the organization's anti-aging project. SBM.VN: 0.115 (-0.005)
Sirona Biochem Announces Successful Synthesis of Anti-Inflammatory Compound for Bloom Burton & Co. Joint Venture
Marketwire - Thu Jul 31, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the "Company"
announces the achievement of the first batch of compound in the joint venture with Bloom Burton & Co. ("Bloom Burton" Compounds developed within the framework of the JV will be entering development in the areas of rare inflammatory and infectious diseases. SBM.VN: 0.115 (-0.005)
Sirona Arranges Convertible Loans
Marketwire - Tue Jul 29, 4:48PM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the "Company"
announces that is has entered into convertible loan agreements with arm's length parties (the "Lenders" for the purposes of renewing current outstanding loans in the total amount of $670,000. The original loans were taken out in late 2012 and became due this quarter. SBM.VN: 0.115 (-0.005)
(0)
(0)Scroll down for more posts ▼